Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib with Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
NCT00293371Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Feb 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatalanib in prostate cancer (PCa), sponsored by University of California, San Francisco. Primary endpoints: Dose-Limiting Toxicities and Maximum Tolerated Dose. Started Feb 2005; status: terminated.
02
Drugs
vatalanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00293371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293371.